Health technology assessment : HTA
-
Health Technol Assess · Aug 2013
ReviewHome telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation.
Remote monitoring (RM) strategies have the potential to deliver specialised care and management to patients with heart failure (HF). ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · Aug 2013
ReviewCost-effectiveness of transcatheter aortic valve implantation (TAVI) for aortic stenosis in patients who are high risk or contraindicated for surgery: a model-based economic evaluation.
Calcific aortic stenosis (AS) is a common valvular heart disease. Patients with severe symptomatic AS typically survive less than 3 years. In such patients, intervention with surgical aortic valve replacement (SAVR) may increase survival. However, in some patients SAVR is associated with a high operative risk and medical management is considered appropriate. Transcatheter aortic valve implantation (TAVI) is a relatively recent technique to avoid the invasiveness of open surgery. This procedure has been used for the treatment of patients with severe AS who are unsuitable for SAVR (because it is too high risk and/or for other reasons such as suffering from porcelain aorta) and is increasingly being considered for other patients. ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · Jul 2013
ReviewSystematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours. ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · Jul 2013
ReviewClinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
The National Institute for Health and Care Excellence (NICE) has issued multiple guidance for the first-line management of patients with lung cancer and recommends different combinations of chemotherapy treatments. This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance. ⋯ The National Institute for Health Research Health Technology Assessment.
-
Health Technol Assess · Jul 2013
ReviewCombined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway. ⋯ The National Institute for Health Research Health Technology Assessment programme.